Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB

Key Points

• Deutsche Bank initiated a position in AnaptysBio during the second quarter, purchasing 46,884 shares worth approximately $3.17 million, or about 0.16% of the company.
• Other institutional investors, including Vanguard, State Street, Affinity Asset Advisors, 683 Capital Management, and Bank of America, also increased their AnaptysBio holdings.
• AnaptysBio shares opened at $58, while analysts maintained an overall “Moderate Buy” consensus with an average price target of $80; ratings included 10 Buys, three Holds, and one Sell.

Deutsche Bank AG purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 46,884 shares of the biotechnology company's stock, valued at approximately $3,165,000. Deutsche Bank AG owned approximately 0.16% of AnaptysBio at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company's stock valued at $74,855,000 after purchasing an additional 67,048 shares during the last quarter. State Street Corp increased its holdings in shares of AnaptysBio by 20.6% during the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company's stock worth $51,072,000 after buying an additional 180,042 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of AnaptysBio by 111.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company's stock valued at $52,132,000 after acquiring an additional 495,308 shares during the last quarter. 683 Capital Management LLC lifted its stake in shares of AnaptysBio by 18.5% in the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 101,093 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of AnaptysBio by 283.2% during the 1st quarter. Bank of America Corp DE now owns 501,086 shares of the biotechnology company's stock valued at $27,790,000 after acquiring an additional 370,319 shares in the last quarter.

AnaptysBio Stock Performance

ANAB stock opened at $58.00 on Thursday. The stock's 50 day simple moving average is $58.58 and its 200 day simple moving average is $59.02. The company has a market cap of $1.72 billion, a P/E ratio of -53.70 and a beta of 0.72. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ANAB shares. Barclays boosted their price objective on AnaptysBio from $63.00 to $75.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 13th. Weiss Ratings restated a "sell (e+)" rating on shares of AnaptysBio in a report on Friday, August 7th. Leerink Partners set a $90.00 price objective on AnaptysBio in a research note on Friday, May 15th. TD Cowen cut their target price on shares of AnaptysBio from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Piper Sandler decreased their price target on shares of AnaptysBio from $95.00 to $93.00 and set an "overweight" rating for the company in a research report on Monday, May 4th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, AnaptysBio currently has an average rating of "Moderate Buy" and an average target price of $80.00.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source